Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more
Zhejiang Orient Gene Biotech Co Ltd (688298) - Total Assets
Latest total assets as of September 2025: CN¥7.51 Billion CNY
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) holds total assets worth CN¥7.51 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Orient Gene Biotech Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zhejiang Orient Gene Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Orient Gene Biotech Co Ltd's total assets of CN¥7.51 Billion consist of 49.2% current assets and 50.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 38.1% |
| Accounts Receivable | CN¥249.28 Million | 3.1% |
| Inventory | CN¥308.96 Million | 3.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥690.91 Million | 8.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Orient Gene Biotech Co Ltd's current assets represent 49.2% of total assets in 2024, a decrease from 70.1% in 2016.
- Cash Position: Cash and equivalents constituted 38.1% of total assets in 2024, up from 33.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 4.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 8.5% of total assets.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Orient Gene Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Zhejiang Orient Gene Biotech Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zhejiang Orient Gene Biotech Co Ltd generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zhejiang Orient Gene Biotech Co Ltd is currently not profitable relative to its asset base.
Zhejiang Orient Gene Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.28 | 4.09 | 2.98 |
| Quick Ratio | 3.86 | 3.71 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.58 Billion | CN¥ 3.45 Billion | CN¥ 2.21 Billion |
Zhejiang Orient Gene Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Orient Gene Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.78 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -10.0% |
| Total Assets | CN¥8.09 Billion |
| Market Capitalization | $298.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Orient Gene Biotech Co Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zhejiang Orient Gene Biotech Co Ltd's assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual total assets of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.09 Billion | -10.02% |
| 2023-12-31 | CN¥9.00 Billion | -15.96% |
| 2022-12-31 | CN¥10.70 Billion | +19.24% |
| 2021-12-31 | CN¥8.98 Billion | +151.23% |
| 2020-12-31 | CN¥3.57 Billion | +888.41% |
| 2019-12-31 | CN¥361.51 Million | +7.07% |
| 2018-12-31 | CN¥337.65 Million | +30.21% |
| 2017-12-31 | CN¥259.32 Million | +7.60% |
| 2016-12-31 | CN¥241.00 Million | -- |